Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Crushed Tebipenem via Nasogastric Tube
NCT05296382Phase 1Completed
- Sponsor
- Hartford Hospital
- Start
- Apr 2022
- Primary completion
- Jun 2022
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tebipenem in complicated urinary tract infection (cUTI) and pyelonephritis (3 arms), sponsored by Hartford Hospital. Primary endpoint: Tebipenem drug exposure at 8 hours. Started Apr 2022; status: completed.
02
Drugs
tebipenem
03
Conditions
complicated urinary tract infection (cUTI)pyelonephritis
Beyond the preview
Go deeper on NCT05296382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296382.